The role of difluprednate ophthalmic emulsion in clinical practice.

Article Details

Citation
Copy to clipboard

Jamal KN, Callanan DG

The role of difluprednate ophthalmic emulsion in clinical practice.

Clin Ophthalmol. 2009;3:381-90. Epub 2009 Jun 29.

PubMed ID
19668594 [ View in PubMed
]
Abstract

The mainstay in the treatment of ocular inflammation, either post-surgical or endogenous, is the use of steroids. While these agents effectively address inflammation, they are not without their risks, including ocular hypertension and acceleration of cataract formation. The most notorious culprits are the strong steroids, such as prednisolone acetate and betamethasone. This review aims to cover the biochemistry and drug development of difluprednate, a novel synthetic strong steroid emulsion. In vivo pharmacokinetics as well as ocular distribution and metabolism are discussed, followed by a comprehensive summary of phase I, II, and III clinical trials evaluating safety and efficacy in patients suffering from postoperative inflammation or anterior uveitis. The objective is to provide an increased familiarity with this newly approved medication as a welcome addition to the ophthalmologist's armamentarium.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
DifluprednateGlucocorticoid receptorProteinHumans
Yes
Agonist
Details